Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Determinants of serum adiponectin in persons with and without type 1 diabetes.

Maahs DM, Ogden LG, Snell-Bergeon JK, Kinney GL, Wadwa RP, Hokanson JE, Dabelea D, Kretowski A, Eckel RH, Rewers M.

Am J Epidemiol. 2007 Sep 15;166(6):731-40. Epub 2007 Jun 24.

PMID:
17591595
3.

Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.

Saraheimo M, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J, Flyvbjerg A, Groop PH; FinnDiane Study Group.

Diabetes Care. 2008 Jun;31(6):1165-9. doi: 10.2337/dc07-2306. Epub 2008 Mar 17.

PMID:
18346990
4.
5.

Determinants of adiponectin levels in young people with Type 1 diabetes.

Barnes MM, Curran-Everett D, Hamman RF, Maahs D, Mayer-Davis EJ, D'Agostino RB Jr, West N, Dabelea D.

Diabet Med. 2008 Mar;25(3):365-9. doi: 10.1111/j.1464-5491.2007.02374.x.

PMID:
18307464
6.

Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease.

Lautamäki R, Rönnemaa T, Huupponen R, Lehtimäki T, Iozzo P, Airaksinen KE, Knuuti J, Nuutila P.

Metabolism. 2007 Jul;56(7):881-6.

PMID:
17570246
7.

High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.

Dullaart RP, de Vries R, Sluiter WJ, Voorbij HA.

Clin Endocrinol (Oxf). 2009 Feb;70(2):221-6. doi: 10.1111/j.1365-2265.2008.03306.x.

PMID:
18505467
8.

Low plasma adiponectin levels predict progression of coronary artery calcification.

Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M.

Circulation. 2005 Feb 15;111(6):747-53. Epub 2005 Feb 7.

9.

Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes.

Wadwa RP, Kinney GL, Ogden L, Snell-Bergeon JK, Maahs DM, Cornell E, Tracy RP, Rewers M.

Int J Biochem Cell Biol. 2006;38(5-6):996-1003. Epub 2005 Oct 18.

PMID:
16271309
10.

Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction.

Aso Y, Suganuma R, Wakabayashi S, Hara K, Nakano T, Suetsugu M, Matsumoto S, Nakamachi T, Takebayashi K, Morita K, Inukai T.

Transl Res. 2009 Oct;154(4):175-82. doi: 10.1016/j.trsl.2009.07.005. Epub 2009 Aug 3.

PMID:
19766961
11.

Increased arterial stiffness in children and adolescents with type 1 diabetes: no association between arterial stiffness and serum levels of adiponectin.

Galler A, Heitmann A, Siekmeyer W, Gelbrich G, Kapellen T, Kratzsch J, Kiess W.

Pediatr Diabetes. 2010 Feb;11(1):38-46. doi: 10.1111/j.1399-5448.2009.00525.x. Epub 2009 May 28.

PMID:
19496970
12.

Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes.

Yano Y, Hoshide S, Ishikawa J, Hashimoto T, Eguchi K, Shimada K, Kario K.

J Clin Hypertens (Greenwich). 2007 Oct;9(10):775-82.

13.

Serum adiponectin and renal dysfunction in men with type 2 diabetes.

Lin J, Hu FB, Curhan G.

Diabetes Care. 2007 Feb;30(2):239-44.

PMID:
17259488
14.

Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration.

Lindström T, Frystyk J, Hedman CA, Flyvbjerg A, Arnqvist HJ.

Clin Endocrinol (Oxf). 2006 Dec;65(6):776-82.

PMID:
17121530
15.

Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link.

Ljubic S, Boras J, Jazbec A, Lovrencic MV, Vidjak V, Erzen DJ, Mileta D.

Clin Invest Med. 2009 Aug 1;32(4):E271-9.

PMID:
19640330
16.

Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes.

Furuhashi M, Ura N, Moniwa N, Shinshi Y, Kouzu H, Nishihara M, Kokubu N, Takahashi T, Sakamoto K, Hayashi M, Satoh N, Nishitani T, Shikano Y, Shimamoto K.

Diabetes Care. 2004 Sep;27(9):2217-21.

PMID:
15333487
17.

Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.

Tsao YT, Hsu YJ, Chu NF, Lai CH, Chiu JS, Lin SH.

J Nephrol. 2008 Sep-Oct;21(5):744-52.

PMID:
18949730
18.

Adiponectin, total antioxidant status, and urine albumin excretion in the low-risk "Golden Years" type 1 diabetes mellitus cohort.

Prior SL, Tang TS, Gill GV, Bain SC, Stephens JW.

Metabolism. 2011 Feb;60(2):173-9. doi: 10.1016/j.metabol.2009.12.008. Epub 2010 Feb 25.

PMID:
20188385
19.

Plasma adiponectin: a predictor of coronary heart disease in hemodialysis patients--a Japanese prospective eight-year study.

Takemoto F, Katori H, Sawa N, Hoshino J, Suwabe T, Nakanishi S, Arai S, Fukuda S, Kodaka K, Shimada M, Yamazaki C, Yokoyama K, Nakano Y, Funahashi T, Ubara Y, Yamada A, Takaichi K, Uchida S.

Nephron Clin Pract. 2009;111(1):c12-20. doi: 10.1159/000178818. Epub 2008 Dec 4.

PMID:
19052467
20.

Periodontal infection profiles in type 1 diabetes.

Lalla E, Kaplan S, Chang SM, Roth GA, Celenti R, Hinckley K, Greenberg E, Papapanou PN.

J Clin Periodontol. 2006 Dec;33(12):855-62.

PMID:
17092237

Supplemental Content

Support Center